REVLIMID® (Lenalidomide) for Therapy of Radioiodine-Unresponsive Papillary and Follicular Thyroid Carcinomas
This study is ongoing, but not recruiting participants.
Sponsor:
University of Kentucky
Collaborator:
Celgene Corporation
Information provided by (Responsible Party):
Kenneth Ain, University of Kentucky
ClinicalTrials.gov Identifier:
NCT00287287
First received: February 3, 2006
Last updated: September 17, 2012
Last verified: September 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Study Status: | This study is ongoing, but not recruiting participants. |
|---|---|
| Estimated Study Completion Date: | No date given |
| Estimated Primary Completion Date: | January 2014 (Final data collection date for primary outcome measure) |